Critical Survey: bioAffinity Technologies (BIAF) vs. Its Rivals

bioAffinity Technologies (NASDAQ:BIAF) is one of 38 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare bioAffinity Technologies to related businesses based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, earnings and profitability.

Profitability

This table compares bioAffinity Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-262.38%	-20.35%	-12.08%

Risk and Volatility

bioAffinity Technologies has a beta of 3.93, suggesting that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ rivals have a beta of 6.20, suggesting that their average stock price is 520% more volatile than the S&P 500.

Institutional and Insider Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 50.9% of shares of all “Commercial physical research” companies are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by company insiders. Comparatively, 15.6% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares bioAffinity Technologies and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.72
bioAffinity Technologies Competitors	$1.30 billion	$81.79 million	7.70

bioAffinity Technologies’ rivals have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for bioAffinity Technologies and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	45	732	1152	26	2.59

As a group, “Commercial physical research” companies have a potential upside of 17.47%. Given bioAffinity Technologies’ rivals higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its rivals.

Summary

bioAffinity Technologies rivals beat bioAffinity Technologies on 8 of the 9 factors compared.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.